| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2024-02-21 | ESHELMAN FREDRIC N | G1 Therapeutics, Inc. | 4,216,074 | 8.1% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | G1 Therapeutics, Inc. | 1,925,845 | 3.8% | EDGAR |
| SC 13G/A | 2023-02-03 | STATE STREET CORP | G1 Therapeutics, Inc. | - | 0.4% | EDGAR |
| SC 13G/A | 2022-12-06 | JPMORGAN CHASE & CO | G1 Therapeutics, Inc. | 2,045,814 | 4.0% | EDGAR |
| SC 13G/A | 2022-07-11 | STATE STREET CORP | G1 Therapeutics, Inc. | - | 0.3% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | G1 Therapeutics, Inc. | 1,369,281 | 3.2% | EDGAR |
| SC 13G/A | 2022-02-11 | STATE STREET CORP | G1 Therapeutics, Inc. | - | 10.1% | EDGAR |
| SC 13G/A | 2022-02-10 | VANGUARD GROUP INC | G1 Therapeutics, Inc. | 2,544,365 | 6.0% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | G1 Therapeutics, Inc. | 3,310,212 | 7.8% | EDGAR |
| SC 13G | 2022-01-21 | JPMORGAN CHASE & CO | G1 Therapeutics, Inc. | 2,139,848 | 5.0% | EDGAR |
| SC 13G/A | 2021-10-12 | STATE STREET CORP | G1 Therapeutics, Inc. | - | 10.4% | EDGAR |
| SC 13G/A | 2021-02-12 | Hatteras Venture Partners IV SBIC, LP | G1 Therapeutics, Inc. | 1,664,001 | 4.4% | EDGAR |
| SC 13G | 2021-02-11 | STATE STREET CORP | G1 Therapeutics, Inc. | - | 6.8% | EDGAR |
| SC 13G/A | 2021-02-10 | VANGUARD GROUP INC | G1 Therapeutics, Inc. | 2,095,727 | 5.5% | EDGAR |
| SC 13G/A | 2021-02-08 | FMR LLC | G1 Therapeutics, Inc. | 923,939 | 2.4% | EDGAR |
| SC 13G/A | 2021-02-03 | WELLINGTON MANAGEMENT GROUP LLP | G1 Therapeutics, Inc. | 1,237,342 | 3.2% | EDGAR |
| SC 13G/A | 2021-01-29 | BlackRock Inc. | G1 Therapeutics, Inc. | 2,893,593 | 7.6% | EDGAR |
| SC 13G/A | 2020-11-10 | FMR LLC | G1 Therapeutics, Inc. | 2,544,537 | 6.7% | EDGAR |
| SC 13G/A | 2020-09-09 | WELLINGTON MANAGEMENT GROUP LLP | G1 Therapeutics, Inc. | 2,956,555 | 7.8% | EDGAR |
| SC 13G/A | 2020-02-11 | Hatteras Venture Partners IV SBIC, LP | G1 Therapeutics, Inc. | 1,910,126 | 5.1% | EDGAR |